Agios Pharmaceuticals, Inc. – NASDAQ:AGIO
Agios Pharmaceuticals stock price today
$36.22
+2.82
+8.44%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Agios Pharmaceuticals stock price monthly change
-27.20%
month
Agios Pharmaceuticals stock price quarterly change
-27.20%
quarter
Agios Pharmaceuticals stock price yearly change
+46.30%
year
Agios Pharmaceuticals key metrics
Market Cap | 1.99B |
Enterprise value | 1.14B |
P/E | -5.4 |
EV/Sales | 80.65 |
EV/EBITDA | -5.45 |
Price/Sales | 84.41 |
Price/Book | 1.09 |
PEG ratio | 0.04 |
EPS | -6.31 |
Revenue | 29.40M |
EBITDA | -390.19M |
Income | -352.61M |
Revenue Q/Q | 45.99% |
Revenue Y/Y | 54.61% |
Profit margin | -1627.82% |
Oper. margin | -2732.07% |
Gross margin | 88.03% |
EBIT margin | -2732.07% |
EBITDA margin | -1327.06% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAgios Pharmaceuticals stock price history
Agios Pharmaceuticals stock forecast
Agios Pharmaceuticals financial statements
Average Price Target
$54.33
Potential upside: 50.00%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 6.71M | -83.80M | -1248.6% |
|---|---|---|---|
| Sep 2023 | 7.39M | -91.32M | -1234.27% |
| Dec 2023 | 7.10M | -95.94M | -1350.7% |
| Mar 2024 | 8.18M | -81.54M | -995.84% |
| Jun 2023 | 1085153000 | 120.91M | 11.14% |
|---|---|---|---|
| Sep 2023 | 1007258000 | 120.41M | 11.95% |
| Dec 2023 | 937118000 | 126.09M | 13.46% |
| Mar 2024 | 849709000 | 105.78M | 12.45% |
| Jun 2023 | -66.74M | 47.12M | 237K |
|---|---|---|---|
| Sep 2023 | -61.64M | 39.34M | 1.88M |
| Dec 2023 | -72.48M | 95.51M | 847K |
| Mar 2024 | -99.86M | 124.56M | 5.86M |
Agios Pharmaceuticals alternative data
| Aug 2023 | 389 |
|---|---|
| Sep 2023 | 389 |
| Oct 2023 | 389 |
| Nov 2023 | 389 |
| Dec 2023 | 389 |
| Jan 2024 | 389 |
| Feb 2024 | 389 |
| Mar 2024 | 389 |
| Apr 2024 | 389 |
| May 2024 | 389 |
| Jun 2024 | 383 |
| Jul 2024 | 383 |
Agios Pharmaceuticals other data
95.51%
-4.49%
of AGIO is owned by hedge funds
143
-6
57.73M
+103.83K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 51588 |
| Feb 2024 | 0 | 139435 |
| Mar 2024 | 0 | 19239 |
| Apr 2024 | 0 | 7791 |
| Jun 2024 | 0 | 13477 |
| Jul 2024 | 0 | 3705 |
| Aug 2024 | 0 | 11091 |
| Sep 2024 | 0 | 2542 |
| Nov 2024 | 0 | 42524 |
| Dec 2024 | 0 | 200 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | SCADDEN DAVID director | Stock options (right to buy) | 200 | $18.09 | $3,618 | ||
Option | SCADDEN DAVID director | Common stock | 200 | $18.09 | $3,618 | ||
Sale | SCADDEN DAVID director | Common stock | 200 | $46.28 | $9,256 | ||
Sale | WASHBURN THEODORE JAMES JR. officer: Principal Accounting O.. | Common stock | 772 | $56.09 | $43,301 | ||
Option | BALLAL RAHUL D. director | Common stock | 10,000 | $25.99 | $259,900 | ||
Option | BALLAL RAHUL D. director | Stock option (right to buy) | 10,000 | $25.99 | $259,900 | ||
Sale | BALLAL RAHUL D. director | Common stock | 3,571 | $57.24 | $204,404 | ||
Sale | BALLAL RAHUL D. director | Common stock | 4,929 | $58.57 | $288,692 | ||
Sale | BALLAL RAHUL D. director | Common stock | 1,500 | $59.21 | $88,815 | ||
Option | BALLAL RAHUL D. director | Stock option (right to buy) | 10,000 | $25.99 | $259,900 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Agios Is A Gem, But It Will Need Patience (Rating Upgrade)
Agios Pharmaceuticals: Strong Thalassemia Data Makes A Tempting Bull Case
Agios Pharmaceuticals: Positive Phase 2 Results In Sickle Cell Study
Agios Pharmaceuticals: Good Execution, A Good Deal Of Cash, Some Hurdles
The Big Short: 5 Stocks At Risk With High Short Interest
Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Agios: Approved Product, Upcoming Catalysts
Agios Pharmaceuticals With FDA Approval Is A Buy
Agios Before The February PDUFA
-
What's the price of Agios Pharmaceuticals stock today?
One share of Agios Pharmaceuticals stock can currently be purchased for approximately $36.22.
-
When is Agios Pharmaceuticals's next earnings date?
Unfortunately, Agios Pharmaceuticals's (AGIO) next earnings date is currently unknown.
-
Does Agios Pharmaceuticals pay dividends?
No, Agios Pharmaceuticals does not pay dividends.
-
How much money does Agios Pharmaceuticals make?
Agios Pharmaceuticals has a market capitalization of 1.99B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 88.36% to 26.82M US dollars.
-
What is Agios Pharmaceuticals's stock symbol?
Agios Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "AGIO".
-
What is Agios Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Agios Pharmaceuticals?
Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Agios Pharmaceuticals's key executives?
Agios Pharmaceuticals's management team includes the following people:
- Dr. Jacqualyn A. Fouse Chief Executive Officer & Director(age: 64, pay: $1,270,000)
- Dr. Bruce Car Ph.D. Chief Scientific Officer(age: 63, pay: $894,800)
- Mr. Jonathan Biller J.D. Chief Financial Officer and Head of Legal & Corporation Affairs(age: 61, pay: $769,330)
-
How many employees does Agios Pharmaceuticals have?
As Jul 2024, Agios Pharmaceuticals employs 383 workers, which is 2% less then previous quarter.
-
When Agios Pharmaceuticals went public?
Agios Pharmaceuticals, Inc. is publicly traded company for more then 12 years since IPO on 24 Jul 2013.
-
What is Agios Pharmaceuticals's official website?
The official website for Agios Pharmaceuticals is agios.com.
-
Where are Agios Pharmaceuticals's headquarters?
Agios Pharmaceuticals is headquartered at 88 Sidney Street, Cambridge, MA.
-
How can i contact Agios Pharmaceuticals?
Agios Pharmaceuticals's mailing address is 88 Sidney Street, Cambridge, MA and company can be reached via phone at +61 76498600.
-
What is Agios Pharmaceuticals stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Agios Pharmaceuticals in the last 12 months, the avarage price target is $54.33. The average price target represents a 50.00% change from the last price of $36.22.
Agios Pharmaceuticals company profile:
Agios Pharmaceuticals, Inc.
agios.comExchange:
NASDAQ
Full time employees:
383
Industry:
Biotechnology
Sector:
Healthcare
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
88 Sidney Street
Cambridge, MA 02139-4169
Cambridge, MA 02139-4169
CIK: 0001439222
ISIN: US00847X1046
CUSIP: 00847X104
